Orexigen to file obesity drug Contrave after positive Phase III data
This article was originally published in Scrip
Executive Summary
Orexigen's lead candidate Contrave (naltrexone sustained-release/bupropion SR) has met the co-primary endpoints of three pivotal Phase III trials, COR-I, COR-II and COR-diabetes, for the treatment of obesity.